Akers Biosciences Share Discussion Threads

[mcmather] 23/1/2015 14:02

Good luck Algernon though I agree with Norbus that the following might be a bit busy at the moment:

Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75)
Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75)
Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75)
Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75)

[mcmather] 23/1/2015 13:59

Cheers Norbus I'll try to have a look. Lack of time and quite tempted for the year ahead re a bit of buying / renovating of property. Nothing definite yet mind.

[norbus] 23/1/2015 12:41

He'll buy you dinner in New Jersey before he replies! don't hold your breath

[algernon2] 23/1/2015 11:15

Dear All,
I have just sent to Akers Biosciences via their website an invitation to Dr Akers to read the last 2 months comments on this Bulletin Board and respond to us via the board and to myself directly(as a shareholder)as he appears not to be inspiring much confidence at the moment.
I will let you know if I get a personal reply and obviously if he replies to us all here then we will hopefully notice that also.
If he doesn't reply himself then hopefully someone close to him will do so shortly?!!
Good afternoon Dr Akers.
Is anybody here yet?
Over to you.

[norbus] 23/1/2015 10:57

mcm

do your self a favour; you have earned and deserve some reward and pleasure; you will not get it here. CAP a recent discovery since tanking below where my kids went in got me to study the form' I liked what I saw and topped up to 2%. Should see fireworks over the very near term and go on. You know all about ITM by now. have a look at likely val in 18 months.

[waylander2] 23/1/2015 09:56

I have been here for some time now. I don't post much as I don't really have much of value to contribute. I appreciate the time and effort MCM has put into this share and keeping us all updated. I has been disappointing to see his disillusionment grow.
The only reason I invested in this company was because I believed the products had real value and potential. However I have to now come to the realisation that I have been taken for a complete ride. I don't believe that AKR are genuinely capable of making a success of this company. The fact that they have some great products only makes the incompetency even more difficult to take.

[mcmather] 23/1/2015 09:11

The below is / was based on the figures achieved in Q1 2014:

$1.2m revenue Q1 2014.
X4 = $5m for 2014 if things simply remain the same each 1/4. Plus anything from:
Chube - comprehensive launch in the US in 2014.
Metron - comprehensive launch in the US in 2014.
VIVO - comprehensive launch in the US in 2014.
Chube - Poland
New sales strategy in the US re the PIFA / Pluss range of products.
The recent 3 year / $5m purchase order in place in Aus / UAE / Singapore / Oman.
The PIFA range of products in China and the tie up with Novotek Therapeutics.


The point again, has the management exceeded what it set out to do at start of 2014 / following Q1 2014 results? If the answer is no then the following persons should NOT have received the following benefits - there is NO DISCERNIBLE REASON OR JUSTIFICATION for doing so; perhaps the management would like to clearly explain to shareholders (myself included) why they have effectively given themselves $675,000 of monies that actually belongs to the entity that is the company and which therefore is owned by shareholders and persons who appear to be predominantly based both here and in the US:

WHY HAVE THE BELOW RECEIVED THE FOLLOWING BENEFITS? PLEASE DISCUSS
Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75)
Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75)
Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75)
Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75)

[mcmather] 23/1/2015 09:00

Of course, 2013 was mainly about Breathalyser stuff with news promised in 2014 re Chube, Metron, etc.

Reference in that first quarter earnings call to a comprehensive US launch of a number of products including Chube, Metron and VIVO in 2014. Keep an eye on the y/e results for 2014 for those products and details of how the comprehensive launch went.

There was also reference to Poland introducing regulation re the disposable breathalyser market for the end of June 2014. Although no one yet knows in what form this will take – their own standard, simply adopting the French NF standard, etc – Chubeworkx have ‘men on the ground...distributors ARE signed up....they effectively have a lobbyist’ who appears to be liaising with the government....Chubeworkx already has the Chube device in Polish labels. In Dr Walt's defence, he was still blurting at this time about it being mandatory for motorists in France to carry 2 disposable breathalysers completely unaware that there was no penalty if you did not. It's not Dr Walt's fault he is a bit clueless.

Whilst they were still awaiting the outcome in Italy and the Netherlands re their proposed regulation in this arena at this time; Poland will introduce regulation re the disposable breathalyser market for the end of June 2014. Although no one yet knows in what form this will take – their own standard, simply adopting the French NF standard, etc – Chubeworkx have ‘men on the ground...distributors ARE signed up....they effectively have a lobbyist’ who appears to be liaising with the government.

[mcmather] 23/1/2015 08:48

This is from the First Quarter 2014 Earnings Call

The PIFA Pluss product range started to be sold by their two main distribution partners in the US as of Jan 2014; “we are already showing a measurable increase in product trial and adoption and we expect further acceleration as Edwin C. Hendrick spearheads the next phase of our commercialisation strategy”.

Hendrick has been on board for just a month. They have already implemented a big change in sales strategy re the PIFA range of products in the US.

The average cost of a Heparin lab test in the US is $1000. The PIFA PF4 costs $55 with the PIFA Pluss device $75. Reference to a hospital undertaking 50 such tests a month. Don’t quite follow how things work in the US but reference made to such costs within pharmacies not being recoverable. The new sales strategy is to target this market; ie the result is the same so why not use this device saving you $900 per test; “We think that this strategy is really going to provide a very significant increase in the uptake of this product.”

Obviously could not disclose how things are advancing re sales but Akers is “really, really excited and optimistic re the new sales strategy...pretty compelling”.

Where has Edwin C Hendrick gone???

[mcmather] 23/1/2015 08:44

WW this was posted on here start of May 2014. Keep an eye on the results for 2014 re where the company achieved revenue:

USA Products
◦BreathScan®
◦BreathScan® PRO
◦CHUBE®
◦METRON®
◦PIFA® Heparin/PF4
◦PIFA PLUSS® PF4
◦Tri-Cholesterol
◦VIVO™

International Products
◦Breath Ketone
◦CHUBE®
◦PaIFA® Heparin/PF4
◦PIFA® Chlamydia
◦PIFA® Dengue Fever
◦PIFA® Malaria
◦PIFA® Syphilis
◦Tri-Cholesterol

[mcmather] 23/1/2015 08:41

Correct WW. So now is not the time to 'reward' key personnel.

[werewolfie] 22/1/2015 18:35

I hear what you are saying McM - but i'm still not feeling its really kicked off yet. (Despite starting long, long ago in a galaxy far, far away)

One more year to see if it is going to kick off - then I will become a much harsher critic/ or I will be looking for an exit

[mcmather] 21/1/2015 22:09

PREDICITION (of sorts and purely my speculations here)

Revenue for H1 2014 was $2,527,076; A.

Revenue for Q3 2014 was $453,313; B

A + B + $1m Chinese order which will, according to Dr Walt, have been shipped before 2014 = $3,980,389.

Total revenue for 2014 just under $4.5m??

Dr Raymond Akers Jr will highlight 'growth' but not mention the many occasions throughout the year when he has alluded to being happy about the suggestion that revenue would be over $5m and/or that the company would be cash neutral by year end.

He will also highlight growing difficulties and the time it takes for new strategies to gain traction.

He will refer to losses by making reference to the cost of new senior management but make no reference to Edwin C. Hendrick.

No reference will be made to the recent issue equity or the options at or under the Nasdaq IPO price; if the performance of the company this year had been outstanding, some kind of a reward for key personnel might have been due. However, one should never reward average and/or very, very average - Q3 2014 was appallingly embarrassing and with silence having befallen Eddie Hendrick I would be surprised if Q4 2014 will be a great deal better, if at all, and this not including the Chinese order which we knew was due from about 18 months ago and which appears to have little correlation to the current management team.

Dr Raymond Akers Jr will meet up with Dave 'The Dandy Highwayman' Gentry. Dave will get paid in his capacity as a paid advisor. Dave will talk about a lot of great stuff and this might include his additional reference to this being a $100m company. But Dave won't question Dr Raymond Akers Jr as to his references throughout the year to the company being cash neutral by year end, why this is not so, why if the performance has been very average the management team have been rewarded with astronomical remuneration deals which are only usually the preserve of large multi-national companies and ones making significant profits, but not companies earning just $453,313 in Q3 2014.

Anymore for anymore?

[mcmather] 21/1/2015 21:41

Norbus, Dr Raymond Akers Jr may well have an exceptional salary and award of shares based upon the miniscule size of the company - just to recap he oversaw revenue of just $453,313 for Q3 2014; crikey, that is embarrassing - but he continues to make himself look a proper laughing stock re his continual inaccurate spoutings and his disastrous record of recruitment.

This from 14 May 2014 off here (#2268) but have a look at how many new sales personnel and tactics we have seen since 2002:

"Key to the achievement of our commercialization strategy," added Dr. Akers, "is the expansion of our internal sales organization and further development of our sales channels. I am pleased to state that we have made significant progress already this year in both of these areas with the recruitment of Edwin C. Hendrick as Executive Vice President, Sales and Maketing and the expansion of distribution agreements with third party distributors."

What has happened to Eddie Hendrick and his position as Executive Vice President, Sales and Marketing? If there was a RNS for his recruitment / arrival should there not be a similar one if he has left / been demoted / etc??

[mcmather] 20/1/2015 16:41

15:34:30 20-Jan-2015 235.25 5,498 12,934.04 Ordinary Trade - delayed publication request.

[rivaldo] 20/1/2015 15:00

From Finncap this morning:

"Akers Biosciences*: Expansion of US sales team (CORP)

Akers has announced the recruitment and deployment of a full-time, pan-US sales and marketing team under the direction of a newly appointed Vice President of Sales and Marketing, John Cheneval. The company has recruited experienced full-time sales representatives based in strategic locations across the US to focus on growing sales of PIFA Heparin/PF4 Rapid Assays. Mr Chevenal has over 25 years of experience in senior positions in diagnostic companies.

We make no changes to our forecasts and retain our 310p target price."

[norbus] 20/1/2015 13:04

Can't get this right, he's done for; why would a good sales & Marketing guy with 25 years work for Dr Walt Mitty? How many heads of S & M have we had since TAN went?

[mcmather] 20/1/2015 11:58

January 20, 2015 - Akers Biosciences, Inc. announces the recruitment and deployment of a full-time, pan-U.S. sales and marketing team under the direction of the newly appointed Executive Vice President, Sales and Marketing, John C. Cheneval.

Mr. Cheneval is a leader in the field of commercializing diagnostic products within the healthcare sector. He has 25 years of high level industry experience.....

Mr. Cheneval has a successful track record of commercializing diagnostic tests and launching novel assays into the market. He has been responsible for the launch and management of several hundred million dollars of diagnostic product sales.

[mcmather] 20/1/2015 11:58

Whacky Walt's Wanderings

March 27, 2014 - Akers Biosciences, Inc. (LSE:AKR) (Nasdaq:AKER), announces the appointment of Edwin C. Hendrick as Executive Vice President, Sales and Marketing.

Mr. Hendrick is a recognized leader.....a career in healthcare that....now spans nearly 25 years, he has led the commercial aspects of diagnostic and healthcare services companies ranging in size from $10 million to $1 billion in revenues.......In every case, Mr. Hendrick contributed to more than doubling or tripling revenues and profitability of those businesses.

In his most recent position, Mr. Hendrick helped lead the company's transformation from a regional lab generating $10 million in revenues to a national leader in its field achieving more than $100 million in revenues.

....Mr. Hendrick built the company's operations and sales and marketing organizations, -leading a team of over 60 to achieve triple-digit growth annually, culminating in US Labs' $155 million acquisition by LabCorp.

.....Mr. Hendrick launched two of the company's biggest selling product lines, contributing to revenue growth from $3 million to over $75million.

[norbus] 16/1/2015 03:05

Aker Billy, and he did have a goat for antibodies, will likely be selling control to the Knoxes under the mulberry tree; That's how they do that kind of thing

[rivaldo] 14/1/2015 15:02

Mcmather, really - 0.001%?!! That equates to a whopping 5,200 shares if I've counted my zeroes correctly.....

To draw conclusions from such tiny numbers is a waste of your and everyone else's time, detracts from your credibility and is certainly not worth posting about :o))

[mcmather] 14/1/2015 09:26

An adverse reaction to the recent 'equity' issue (aka directors awarding themselves money in my name and that of other shareholders who own the company)??

14 Jan 2015 Akers Biosciences Inc (NASDAQ:AKER) may face some pressure in the coming sessions. The short interest has registered a change of 90.95% for the month. The total shorted shares measure up to 0.001 times the outstanding shares.

[azzi] 09/1/2015 21:20

Thanks WereWolfe and algernon2 for your responses!
Yes Dr Walt should certainly keep his lab coat on! Some of his recent comments suggests he is simply looking for the potential blockbuster so that he can be the first to exit.
Algernon, I like the sound of Italian styling, I drive an Italian car of course (Fiat), however in the clinic the reliability of the result is king.
Az